Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
暂无分享,去创建一个
Xavier Montalban | James Sheridan | X. Montalban | J. Simon | T. Vollmer | J. Sheridan | J. Elkins | M. Kaufman | J. Rose | Timothy Vollmer | John W Rose | Daniel Wynn | Alice Fong | G. O'neill | Michael Kaufman | Jacob Elkins | Gilmore O'Neill | Jack Simon | Lauri Neyer | Chungchi Wang | Alice Fong | D. Wynn | L. Neyer | Chungchi Wang
[1] T. Waldmann,et al. Advances in interleukin 2 receptor targeted treatment , 2000, Annals of the rheumatic diseases.
[2] David E. Anderson,et al. IL2RA Genetic Heterogeneity in Multiple Sclerosis and Type 1 Diabetes Susceptibility and Soluble Interleukin-2 Receptor Production , 2009, PLoS genetics.
[3] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[4] H. Wiendl,et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells , 2007, Clinical and experimental immunology.
[5] J. Rose,et al. Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody , 2004, Annals of neurology.
[6] P. Rutgeerts,et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. , 2003 .
[7] H. McFarland,et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. , 2009, Archives of neurology.
[8] E. Reed,et al. Assessing Relative Risks of Infection and Rejection: A Meta-analysis using an Immune Function Assay , 2006, Transplantation.
[9] Stephen Sawcer,et al. The complex genetics of multiple sclerosis: pitfalls and prospects , 2008, Brain : a journal of neurology.
[10] G. Gastl,et al. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti‐CD25 monoclonal antibodies , 2003, Clinical and experimental immunology.
[11] S. Gabriel,et al. Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.
[12] T. Waldmann,et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. , 2009, Archives of neurology.
[13] T. Waldmann,et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Rose,et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis , 2007, Neurology.
[15] Hanne F. Harbo,et al. Refining genetic associations in multiple sclerosis , 2008, The Lancet Neurology.
[16] María M. Abad-Grau,et al. IL2RA/CD25 Gene Polymorphisms: Uneven Association with Multiple Sclerosis (MS) and Type 1 Diabetes (T1D) , 2009, PloS one.
[17] T. Waldmann,et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[18] S. John,et al. IL-2 Receptor Blockade Inhibits Late, But Not Early, IFN-γ and CD40 Ligand Expression in Human T Cells: Disruption of Both IL-12-Dependent and -Independent Pathways of IFN-γ Production , 2002, The Journal of Immunology.
[19] H. Rossman. Neutralizing antibodies to multiple sclerosis treatments. , 2004, Journal of managed care pharmacy : JMCP.
[20] Pablo Tamayo,et al. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. , 2008, Brain : a journal of neurology.
[21] A. Gottlieb,et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. , 2000, Journal of the American Academy of Dermatology.
[22] David H. Miller,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.
[23] L. Kappos,et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. , 2005 .
[24] George Scott,et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.